Schwazze provides update on delayed filings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 04 2024
0mins
Should l Buy ?
Delayed Filings Update: Medicine Man Technologies, operating as Schwazze, announced that it will restate its previously issued financial statements for the fiscal years ending December 31, 2023, due to necessary accounting adjustments identified by the Audit Committee and Baker Tilly.
Impact of Corrections: The company stated that these corrections are material and previous financial reports should no longer be relied upon; however, they do not expect any negative impact on revenue, adjusted EBITDA, cash from operations, or cash position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
